SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors

JERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Steven K. Burke, M.D., to its Board of Directors, effective September 18, 2026.

Dr. Burke brings more than 30 years of industry experience, with a particular focus on drug development for chronic kidney disease. He has worked at Akebia Therapeutics, Inc. since 2019, and has served as its Senior Vice President, Chief Research and Development Officer and Chief Medical Officer since 2021. Dr. Burke has responsibility for Akebia’s research and development functions, including research, toxicology, pharmacology, clinical operations, data management, biostatistics, clinical research, regulatory affairs, drug safety and pharmacovigilance, and medical affairs. During his time, he has had a leadership role in the development of Vafseo® (vadadustat) for anemia due to chronic kidney disease and has supported Auryxia® (ferric citrate). He also oversees development programs including praliciguat and ebribafusp alfa for glomerular diseases and other investigational programs. Prior to joining Akebia, Dr. Burke founded Abfero Pharmaceuticals, Inc. and served on its board through its acquisition by Pharmacosmos A/S. Earlier in his career, Dr. Burke served as Senior Vice President and Chief Medical Officer of Proteon Therapeutics, Inc. from 2006 to 2019 and in senior positions at several other biotechnology companies including Genzyme Inc.